Onco Actu du 21 mars 2016

	4. Dépistage, diagnostic et pronostic
The Myriad myRisk® Hereditary Cancer Test Identifies 60 Percent More Deleterious Mutations in Patients with Endometrial Cancer [Myriad] Details about the featured Myriad presentations at the 2016 Society for Gynecologic Oncology annual meeting are below.
	4.2 Dép., diag. & prono. - Génome
Affymetrix Rejects $1.5 Billion Takeover Bid [NY Times] In a statement, Affymetrix said that the $1.5 billion offer by some of its former employees, who have set up a shell company called Origin Technologies, was not a “superior proposal” to the Thermo Fisher deal.
	5.2.2 Pharma - Fusions & Acquisitions
Omnis, Magnis Merge Into Vyriad, With Focus on Cancer Immunotherapies [GEN] Vyriad’s pipeline of oncolytic virotherapies consists of eight in clinical phases and seven in late-stage preclinical development.
	5.3 Traitements - FDA, EMA,...
NIH, FDA Release Streamlined Clinical Trial Protocol Template [RAPS] According to Marks, the new template will help fill a gap left by international standards for drug and device trials.
EMA recommends new safety measures for Zydelig [EMA] The PRAC recommends that all patients treated with Zydelig should receive antibiotics to prevent a particular type of lung infection (Pneumocystisjirovecii pneumonia). Patients should also be monitored for infection and have regular blood tests for white cell counts because low counts can increase their risk of infection.
FDA and NIH Release a Draft Clinical Trial Protocol Template for Public Comment [FDA Voice] We see the template as a way to facilitate creativity and innovation, not inhibit it.
	5.4 Traitements - Economie
UK cost agency backs J&J cancer drug in change of heart [Reuters] Paul Workman, chief executive of the Institute of Cancer Research in London, whose scientists discovered the medicine, said the latest NICE decision was good news but he criticized the agency for a three-year delay in reaching the verdict.
NICE recommends abiraterone for prostate cancer [NICE] NICE has issued final guidance recommending abiraterone (marketed as Zytiga by Janssen) for some prostate cancer patients*. This is a change from the appraisal committee’s previous draft guidance decision.
	6.1 Observation
Contralateral Prophylactic Mastectomies Are Worse Than Useless for Most Breast Cancer [The Incidental Economist] Contralateral prophylactic mastectomies. Not helping. No one seems to care.
With cancer in one breast, no survival advantage in removing second one [Reuters] For the study, published in the Annals of Surgery, Golshan and colleagues analyzed a nationwide cancer database, focusing on 496,488 women diagnosed with stage I, II and III cancers in only one breast between 1998 and 2012.
	6.10 Politiques
Biden to name former Gore aide as head of cancer task force [STAT] In 2008, Nature named Simon one of their 10 people to watch in biomedical policy. “He is known for bringing disparate groups together to find new ideas,” the journal wrote.
	6.11 Patients
'I nearly died in a medical drug trial' [BBC News] He was taking part in the first human trial of what was known as TGN1412, a drug that manipulated the immune system. The German company that developed the drug hoped it would revolutionise treatment of leukaemia and rheumatoid arthritis.
‘I’m 16. Five months ago, I was diagnosed with terminal cancer’ [The Guardian] Now I measure time in distinct chunks, focusing on events – a holiday or a party. Although it has been an intense few months, I’ve tried not to dwell on it.
	6.6 Publications
Seven Things Every Researcher Should Know About Scholarly Publishing [The Scholarly Kitchen] After many and long conversations among colleagues within and beyond the Scholarly Kitchen about what researchers need to know about scholarly publishing, and drawing on their suggestions and past posts, we have compiled here a list of what we think to be the most urgent issues.
	6.9 Controverses
Brigham Doc's NEJM Paper Decries Morcellation's Demise—Did She Get Confidential Patient Information? [The Cancer Letter] Clearly, Lisa Rosenbaum wanted to trigger a heated discussion—but not of the sort she ended up with.